Claris Ventures is a venture capital firm established in 2019 and based in Turin, Italy. The firm specializes in early-stage investments in high-potential biopharmaceutical companies that emerge from the Italian research and development ecosystem. By focusing on innovative biopharma ventures, Claris Ventures aims to support the growth of companies that are poised to make significant contributions to the healthcare sector.
Iama Therapeutics is focused on neuroscience drug discovery, aiming to develop innovative medicines for children with brain disorders. The company specializes in creating novel therapeutics designed to address neurological conditions such as Down syndrome and autism spectrum disorders. Their treatments target learning and memory difficulties, as well as behavioral challenges commonly associated with these conditions. In addition to developing effective drug solutions, Iama Therapeutics is dedicated to supporting families impacted by these disorders, striving to improve the quality of life for both patients and their caregivers.
NeoPhore
Series B in 2024
NeoPhore Ltd is a biotechnology company based in Cambridge, United Kingdom, that specializes in the discovery and development of small molecule therapies aimed at treating cancer by stimulating the immune system. Founded in 2017, NeoPhore focuses on creating novel therapeutics that target genetic mechanisms to generate neoantigens. These neoantigens are designed to enhance the immune response against tumor cells, potentially exploiting vulnerabilities in their defense mechanisms. By harnessing this approach, NeoPhore aims to improve clinical outcomes for cancer patients through innovative immuno-oncology treatments.
Resalis Therapeutics
Series A in 2024
Resalis Therapeutics is a biopharmaceutical company focused on transforming the treatment of metabolic diseases, particularly obesity and fatty liver disease, by developing innovative therapies that target key regulatory pathways. The company's leading program, RES-010, utilizes its expertise in non-coding RNA drug modalities and lipid metabolism to create a treatment that aims for long-term weight loss and reduced liver fat accumulation. With a strong foundation of preclinical evidence, Resalis is progressing RES-010 into clinical trials, offering potential disease-modifying effects and a safe, convenient therapeutic option for patients suffering from various metabolic disorders.
ALKemist Bio
Seed Round in 2023
ALKemist Bio is focused on developing innovative cell treatments for cancer patients, specifically targeting ALK-positive cancer cells. The company is engaged in the creation of TCR-T cells designed to recognize ALK antigens present on these cancer cells, with a primary emphasis on treating non-small cell lung cancer. By harnessing the power of the immune system and engineering T cells for precise targeting, ALKemist Bio aims to provide more effective treatment options that enhance the standard of care for patients suffering from this type of cancer.
Repron Therapeutics
Seed Round in 2023
Repron Therapeutics focuses on developing innovative treatments for patients with solid tumors that cannot be completely removed through surgery, where the likelihood of metastasis or recurrence is significantly high. The company leverages advanced healthcare technology to inhibit oncogene activity based on tumor characteristics, utilizing engineered synthetic factors. This approach aims to target and eliminate residual tumor cells at the primary site or address micro-metastases in critical organs, thereby improving outcomes for patients facing challenging cancer diagnoses. Repron Therapeutics is committed to addressing the complexities of tumor malignancy and enhancing treatment options in oncology.
Resalis Therapeutics
Seed Round in 2023
Resalis Therapeutics is a biopharmaceutical company focused on transforming the treatment of metabolic diseases, particularly obesity and fatty liver disease, by developing innovative therapies that target key regulatory pathways. The company's leading program, RES-010, utilizes its expertise in non-coding RNA drug modalities and lipid metabolism to create a treatment that aims for long-term weight loss and reduced liver fat accumulation. With a strong foundation of preclinical evidence, Resalis is progressing RES-010 into clinical trials, offering potential disease-modifying effects and a safe, convenient therapeutic option for patients suffering from various metabolic disorders.
NeoPhore
Series B in 2023
NeoPhore Ltd is a biotechnology company based in Cambridge, United Kingdom, that specializes in the discovery and development of small molecule therapies aimed at treating cancer by stimulating the immune system. Founded in 2017, NeoPhore focuses on creating novel therapeutics that target genetic mechanisms to generate neoantigens. These neoantigens are designed to enhance the immune response against tumor cells, potentially exploiting vulnerabilities in their defense mechanisms. By harnessing this approach, NeoPhore aims to improve clinical outcomes for cancer patients through innovative immuno-oncology treatments.
Sibylla Biotech
Series A in 2022
Sibylla Biotech S.R.L. is an Italian company focused on advancing rational drug design in the pharmaceutical sector. The company specializes in the research, development, and production of innovative therapeutic solutions, particularly through the creation of small molecule folding interfering degraders (FIDs) that target a variety of therapeutic areas. Additionally, Sibylla Biotech provides consultancy services in biotechnology and drug development. The company utilizes patent-based software that applies advanced algorithms and drug design protocols, enabling efficient drug discovery by optimizing reaction paths and streamlining data processes. This approach aims to enhance the rationalization of drug discovery efforts, ultimately contributing to the treatment of challenging medical conditions.
Kither Biotech
Series B in 2022
Kither Biotech s.r.l. is a pharmaceutical company based in Turin, Italy, focused on the research and development of drugs and therapies for pulmonary diseases. Founded in 2011, the company is dedicated to addressing unmet medical needs in chronic inflammatory conditions. Its main products include the KIT2014 peptide, developed internally for the treatment of cystic fibrosis, which has received Orphan Drug designation from the European Medicines Agency and is currently in the pre-clinical development phase. Additionally, Kither is advancing the development of a molecule known as CL27, aimed at treating chronic obstructive pulmonary diseases and allergic asthma, and is preparing to enter its pre-clinical phase. Through its innovative research efforts, Kither Biotech seeks to provide effective treatments for patients suffering from various respiratory diseases.
Resalis Therapeutics
Seed Round in 2021
Resalis Therapeutics is a biopharmaceutical company focused on transforming the treatment of metabolic diseases, particularly obesity and fatty liver disease, by developing innovative therapies that target key regulatory pathways. The company's leading program, RES-010, utilizes its expertise in non-coding RNA drug modalities and lipid metabolism to create a treatment that aims for long-term weight loss and reduced liver fat accumulation. With a strong foundation of preclinical evidence, Resalis is progressing RES-010 into clinical trials, offering potential disease-modifying effects and a safe, convenient therapeutic option for patients suffering from various metabolic disorders.
NeoPhore
Series B in 2021
NeoPhore Ltd is a biotechnology company based in Cambridge, United Kingdom, that specializes in the discovery and development of small molecule therapies aimed at treating cancer by stimulating the immune system. Founded in 2017, NeoPhore focuses on creating novel therapeutics that target genetic mechanisms to generate neoantigens. These neoantigens are designed to enhance the immune response against tumor cells, potentially exploiting vulnerabilities in their defense mechanisms. By harnessing this approach, NeoPhore aims to improve clinical outcomes for cancer patients through innovative immuno-oncology treatments.
Kither Biotech
Series A in 2019
Kither Biotech s.r.l. is a pharmaceutical company based in Turin, Italy, focused on the research and development of drugs and therapies for pulmonary diseases. Founded in 2011, the company is dedicated to addressing unmet medical needs in chronic inflammatory conditions. Its main products include the KIT2014 peptide, developed internally for the treatment of cystic fibrosis, which has received Orphan Drug designation from the European Medicines Agency and is currently in the pre-clinical development phase. Additionally, Kither is advancing the development of a molecule known as CL27, aimed at treating chronic obstructive pulmonary diseases and allergic asthma, and is preparing to enter its pre-clinical phase. Through its innovative research efforts, Kither Biotech seeks to provide effective treatments for patients suffering from various respiratory diseases.
Lever Bio
Lever Bio is a biotechnology company focused on advancing immuno-oncology therapies. It collaborates with top researchers and institutions to develop innovative treatments that enhance the body's immune response to cancer, with a particular emphasis on solid tumors. The company's approach involves reprogramming both the metabolic and immune systems to overcome resistance to existing therapies, thereby improving patient outcomes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.